AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02793297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: refined wheat crisp bread
Description: Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
Study NCT02793297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sourdough fermented rye crisp bread
Description: Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
Study NCT02793297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unfermented rye crisp bread
Description: Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
Study NCT04439513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostasis
Description: Compression device to achieve hemostasis.
Study NCT04439513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemostasis
Description: Compression device to achieve hemostasis.
Study NCT01830166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Dose Radiation Focal Brachytherapy
Description: Low Dose Radiation Focal Brachytherapy
Study NCT03464071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperinflation with mechanical ventilator
Description: increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
Study NCT03464071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation
Description: the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
Study NCT03155282 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-E to measure liver and spleen stiffness.
Description: The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
Study NCT04594343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: The subject will receive 500 mg of disulfiram orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Study NCT04594343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive a matching placebo orally or enterally through NG tube if in mechanical ventilation once daily for 14 days
Study NCT01284101 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the Tan Endoglide to insert the donor graft
Description: Using the Tan Endoglide to insert the donor graft into the eye
Study NCT01284101 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forceps for delivery of the donor graft
Description: Use of the forceps for delivery of the donor graft into the eye.
Study NCT01869439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gold standard LxW manual ruler measurement technique
Description: Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length).
Study NCT01869439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's LxW measurement technique
Description: This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
Study NCT00666939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
Study NCT00666939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
Study NCT00666939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study NCT00196365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
Description: 1 tablet daily
Study NCT00196365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Description: 1 tablet daily
Study NCT03646669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Feedback
Description: Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
Study NCT03646669 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma education
Description: General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
Study NCT03085017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BoneSeal
Description: BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
Study NCT03085017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostene
Description: OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
Study NCT04483882 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tactile Labels for Drug identity and dose frequency
Description: The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
Study NCT04483882 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tactile Labels for Drug identity and dose frequency
Description: The tactile labeling proposed in this protocol is rigid labeling. A ring-clip has an inner diameter of 12.5cm, an outer diameter of 16 cm, and a height of 1.5 cm. The ring is cut at 2 cm to form a semi-circle allowing it to be clipped onto the bottleneck. The ring clip fits most if not all prescription eye drop bottles. The individual protrusions with shapes at the end can be cut off by the pharmacist to match the frequency of administration prescribed.
Study NCT01869439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's Visual External Wound Trace
Description: This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
Study NCT01869439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WMMS ImageReview software's External Wound Trace Overlay
Description: This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
Study NCT05133752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemonoxacin
Description: 500 mg, oral administration, once daily for 7-10 days.
Study NCT03172403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Height and weight
Description: Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
Study NCT03172403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
Study NCT03172403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle force
Description: Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
Study NCT03172403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Description: Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
Study NCT03172403 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
Study NCT03380975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
Study NCT04928872 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Predefined meal
Description: Nine predefined meals are administered in a randomized fashion, one meal per one study day, 2-3 study days per week. Meals have a form of drinks with different compositions of protein, carbohydrates and fat in relation to the US diet
Study NCT00370448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
Study NCT00370448 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
Study NCT00370448 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: school-based social support system
Description: Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
Study NCT02831114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
Study NCT02877199 — intervention group
Intervention type: OTHER
Intervention: Triple therapy
Description: Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
Study NCT01188629 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety Training
Description: IT intervention focuses on safety in the home.
Study NCT01188629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Health Partner and Counseling (PHP+C)
Description: The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
Study NCT00364442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: investigational drug
Study NCT03681691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: transdermal 17β-estradiol patch
Study NCT01516892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
Study NCT01360190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: fluoxetine 20 mg. daily
Study NCT01360190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoxetine
Description: fluoxetine 20 mg. daily
Study NCT03155490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership training
Description: Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
Study NCT00938340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut meat
Description: Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
Study NCT00938340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Oil
Description: Walnut oil extracted from nut meat and incorporated into inert food carrier
Study NCT00938340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Skins
Description: Separated, ground walnut skins incorporated into inert food carrier
Study NCT00938340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole walnut
Description: 85g whole walnuts, ground, incorporated into inert food carrier
Study NCT05163756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW1903
Description: q.d. PO, DW1903 + Placebo of DW1903-R1
Study NCT05163756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DW1903-R1
Description: q.d. PO, Placebo of DW1903 + DW1903-R1
Study NCT02334306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 557/MEDI5872
Description: Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
Study NCT02334306 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
Study NCT02374203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high protein enteral nutrition
Description: supply protein over 1.5 gm/kg body weight
Study NCT00893451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (TillVal-D)
Description: In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
Study NCT00893451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice daily
Study NCT02124902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT01923857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study NCT01665417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Icotinib: 125mg, oral administration, three times per day.
Study NCT01665417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 1：Pemetrexe 500 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Study NCT01665417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy Regimen 2：Docetaxel 75 mg/m\^2 on Day 1, Cisplatin 75 mg/m\^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
Study NCT01370278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
Study NCT02124902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01370278 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
Study NCT01668563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical management
Description: Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
Study NCT01668563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular management
Description: Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
Study NCT02004756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
Study NCT03988829 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-C
Description: This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
Study NCT03988829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-C
Description: In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
Study NCT03988829 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-C+
Description: A commercial video game will be used that requires a lot of demand on attentional control.
Study NCT02385825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Description: The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
Study NCT02124902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET/MR
Description: * Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~* This is not optional for final 30 participants enrolled on the study
Study NCT00571363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard surgery
Description: excision with 4 mm margins